The RAMPP study aims to investigate the use of a pleural vent (rocket) versus standard care in patients with Primary Spontaneous Pnuemothorax in a randomised controlled trial.
1. Presenting with primary spontaneous pneumothorax as confirmed by a chest radiograph or a CT scan.
2. Age >= 18 years old and <= 55 years old.
3. Ability to consent to participation.
1. Known or suspected underlying lung disease (including >20 pack year smoking history).
2. Evidence of tension pneumothorax (these patients should be treated immediately as medical emergencies).
3. Females who are pregnant or lactating.
4. Inability to consent or comply with the trial requirements.
5. Contraindication to thoracic procedure. (Only applies to patients being enrolled into Intervention or Control arms – i.e. not observational cohort).
6. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.
Funding: Medical Research Council and the National Institute for Health Research (UK).
Sponsor: University of Oxford, Churchill Hospital (UK)
Setting: This is a multi-centre study being co-ordinated from Oxford.
The study with PP100-01 in combination with NAC is designed to determine safety and tolerability of PP100-01 when co-administered with NAC as compared to the 12-hr NAC treatment regime for patients that come to the hospital after an overdose of paracetamol/acetaminophen.
A Randomised Open Label Exploratory, Safety and Tolerability Study with PP100-01 in Patients Treated with the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose
Tranexamic acid for the treatment of gastrointestinal haemorrhage: an international randomised, double blind placebo controlled trial
Tranexamic acid for the treatment of gastrointestinal haemorrhage